Skip to content
The Weight Clinic
← Blog Wegovy — injection & tablet

Average weight loss on Wegovy in 3 months?

Wegovy semaglutide weekly injection pen on a clean surface with a tape measure
Medically reviewed by Ali Al Sibahi, Pharmacist Independent Prescriber (GPhC 2225108) · 15 November 2026

There is no single official average weight loss on Wegovy (semaglutide) at exactly three months, because the first weeks are a gradual dose build-up rather than a full-strength phase. In the main clinical trials, most of the weight loss accumulated steadily over the full treatment period, so a commonly observed early pattern is a loss of roughly 5–10% of starting body weight by around month three — with wide individual variation. Individual results vary; not everyone reaches this.

Below is a practical, UK-focused explanation of why three months is an early milestone, what influences your result, and how to tell whether your progress is on track.

Why can't a single "3-month average" be quoted for Wegovy?

A single three-month average cannot be quoted for Wegovy because the published trial figures report total weight loss over the full study, not a verified snapshot at week 12. The only efficacy figure we state is from the completed trial: in the STEP UP clinical trial, adults on the 7.2mg dose lost on average 20.7% of their body weight over 72 weeks, alongside lifestyle support. Individual results vary; not everyone reaches this.

At three months most people are still increasing their dose, so they have not yet reached the strength at which appetite reduction is strongest. Early results therefore tend to be smaller than the headline figure and should be read as a starting trajectory, not a final outcome.

How does Wegovy work, and why does that affect early results?

Wegovy is a GLP-1 receptor agonist — it mimics a natural gut hormone that controls appetite, so you feel fuller sooner and for longer, and the stomach empties more slowly. Because it reduces appetite rather than forcing rapid loss, weight comes off gradually and steadily rather than all at once.

In the first three months you are usually still climbing through the lower doses, where the appetite effect is building. That is why month three is better judged by a downward trend and changing eating habits than by hitting a specific number. You can read more on the Wegovy injection page.

What is the Wegovy injection dose schedule in the first 3 months?

The Wegovy injection is a once-weekly self-injection that starts low and increases roughly every four weeks, so that around the three-month mark many people are only reaching the middle doses. The licensed titration is:

  1. 0.25mg — weeks 1–4 (starter dose, mainly to let your body adjust)
  2. 0.5mg — weeks 5–8
  3. 1mg — weeks 9–12
  4. 1.7mg — next step up
  5. 2.4mg — the standard dose
  6. 7.2mg — the maximum licensed dose

So at the end of three months a typical patient has just reached around the 1mg dose. This is one of the main reasons early weight loss is modest compared with the full-trial figure — the dose that drives the strongest appetite effect comes later. Your prescriber adjusts the pace based on how you tolerate each step.

What affects how much you lose on Wegovy in 3 months?

How much you lose in the first three months on Wegovy depends on several factors, which is why two people on the same dose can get different results:

  • How quickly you titrate — some people stay longer on a dose to manage side effects, which slows early loss.
  • Your starting weight — results are usually described as a percentage of body weight, so the same percentage is more kilograms for a heavier starting point.
  • Diet and activity — in every trial the medicine was given alongside lifestyle support; food choices and movement still matter.
  • Consistency — missed or delayed weekly doses reduce the steady appetite effect.
  • Individual biology — appetite response to GLP-1 medicines genuinely varies from person to person.

Is losing less than 5% in 3 months a problem?

Losing less than 5% of your body weight in the first three months on Wegovy is not necessarily a problem, because at that point many people are still on the lower build-up doses where the appetite effect has not fully developed. A slow but steady downward trend, with reduced appetite and smaller portions, is a reasonable early sign.

That said, if you are seeing no change at all, or you are struggling with side effects, this is worth raising with your prescriber. They may adjust your titration or review whether the treatment suits you. Treatment is reviewed on an ongoing basis — you can reach the team via contact us.

What side effects are common in the first 3 months?

The most common Wegovy side effects (affecting more than 1 in 10 people) appear mostly during the first weeks and around each dose increase, because that is when your body is adjusting. They include:

  • Nausea
  • Diarrhoea
  • Constipation
  • Vomiting
  • Decreased appetite
  • Fatigue

Rare but serious effects include severe allergic reaction, acute pancreatitis, severe hypoglycaemia and severe gastrointestinal disease; seek urgent medical help for symptoms such as severe, persistent abdominal pain. You can report any suspected side effect through the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/.

How does Wegovy compare with other weight-loss options over 3 months?

Several medicines we supply reduce appetite through gut-hormone pathways, but they are not interchangeable and no dose equivalence can be implied. The table below shows the headline trial figures (each over its own full study length, not a three-month figure, and not a head-to-head comparison). Individual results vary; not everyone reaches these.

MedicineFormTrial figure (full study)
Wegovy injectionOnce-weekly injection20.7% at 7.2mg over 72 weeks (STEP UP)
Wegovy TabletOnce-daily tablet (empty stomach)16.6% at 25mg over 64 weeks (OASIS 4)
MounjaroOnce-weekly injection22.5% at 15mg over 72 weeks (SURMOUNT-1)
FoundayoOnce-daily tablet (any time)12.4% at 36mg over 72 weeks (ATTAIN-1, trial capsule dose above our maximum tablet)

These are cross-trial numbers measured over different durations, not three-month results, and which medicine suits you is a clinical decision. You can see the full range on the treatments overview and the weight-loss injections page.

Who is eligible for Wegovy in the UK?

Wegovy is a prescription-only medicine available in the UK only after a clinical consultation with a GPhC-registered prescriber. You may be eligible if you are aged 18 or over and have a BMI of 30 or more, or a BMI of 27 or more with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea.

It is not suitable if you are pregnant, planning pregnancy or breastfeeding; have type 1 diabetes; have a personal or family history of medullary thyroid carcinoma or MEN2; have a history of pancreatitis, severe gastrointestinal disease, an active eating disorder, severe liver or kidney impairment, or a known allergy to the active ingredient. A free online consultation checks whether treatment is clinically appropriate for you — a prescription is only issued if it is, and is never guaranteed.

This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.

Related reading

Check eligibility →